HIGHLIGHTS
- who: Transplantation and collaborators from the State Key Laboratory of Experimental Hematology, Department of Hematopoietic Stem Cell, National Clinical Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China Aichi Medical University, Japan have published the research work: Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation, in the Journal: (JOURNAL)
- what: The authors aimed to investigate the effect of ruxolitinib in newly diagnosed BOS post HSCT as a first-line therapy in this study. response (NR) was defined by worsened clinical . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.